Treating the primary tumor for prostate cancer that has spread a little
Part of Cancer, Kidney & urinary clinical trials.
This trial studies whether treating the main prostate tumor with local therapy (like surgery or radiation) along with hormone therapy is beneficial for men whose cancer has spread to only a few spots in the body (low-volume metastases). It focuses on men who have not had any prior treatment for their prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed prostate cancer that has spread to a few places (less than 4 bone spots, no spread to organs like liver or lungs).
- Your cancer was confirmed by a prostate biopsy and does not have a rare type called neuroendocrine cells.
- You have not had any previous treatment for prostate cancer, such as surgery or radiation.
- You have been on hormone therapy for less than 6 months, or haven't started it yet.
- You are generally healthy and able to go about your daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach using radiation therapy (radiotherapy) combined with hormone therapy before the standard surgery to remove the prostate. It aims to see if this combination can better control prostate cancer that has spread to a few spots (oligometastatic) and improve outcomes.
The trial looks at how well local treatment (surgery or radiation) works for prostate cancer that has spread to only a few places, as found on a PSMA PET scan. It aims to see if treating the prostate and its local spread can help people live longer or better.
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
This trial tests whether radiation therapy can help treat prostate cancer that has spread to only a few places in the body (oligometastatic). It aims to see if targeting both the prostate and the small number of metastases can improve outcomes.
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
Hear when a new Oligometastatic Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.